Delcath Systems, Inc. – NASDAQ:DCTH
Delcath Systems stock price today
$10.55
-1.41
-11.79%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Delcath Systems stock price monthly change
+48.20%
month
Delcath Systems stock price quarterly change
+48.20%
quarter
Delcath Systems stock price yearly change
+194.58%
year
Delcath Systems key metrics
Market Cap | 343.71M |
Enterprise value | 48.25M |
P/E | -1.46 |
EV/Sales | 12.39 |
EV/EBITDA | -0.96 |
Price/Sales | 13.08 |
Price/Book | -8.69 |
PEG ratio | -0.02 |
EPS | -2.65 |
Revenue | 4.60M |
EBITDA | -40.03M |
Income | -49.78M |
Revenue Q/Q | 425.79% |
Revenue Y/Y | 56.75% |
Profit margin | -1396.2% |
Oper. margin | -1293.79% |
Gross margin | 76.91% |
EBIT margin | -1293.79% |
EBITDA margin | -868.9% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDelcath Systems stock price history
Delcath Systems stock forecast
Delcath Systems financial statements
| Jun 2023 | 495K | -7.20M | -1454.95% |
|---|---|---|---|
| Sep 2023 | 434K | -20.34M | -4686.64% |
| Dec 2023 | 539K | -11.13M | -2066.05% |
| Mar 2024 | 3.13M | -11.11M | -353.97% |
| Sep 2025 | 19.69M | -2.07M | -10.55% |
|---|---|---|---|
| Oct 2025 | 20.30M | -580.69K | -2.86% |
| Dec 2025 | 26.39M | 650.21K | 2.46% |
| Dec 2025 | 23.75M | 663.66K | 2.79% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 21050000 | 21.29M | 101.15% |
|---|---|---|---|
| Sep 2023 | 47577000 | 22.85M | 48.04% |
| Dec 2023 | 38613000 | 22.83M | 59.14% |
| Mar 2024 | 36099000 | 21.47M | 59.5% |
| Jun 2023 | -9.64M | -40K | 7K |
|---|---|---|---|
| Sep 2023 | -9.16M | 1K | 35.07M |
| Dec 2023 | -8.17M | -19.67M | 1K |
| Mar 2024 | -9.58M | 4.66M | 4.02M |
Delcath Systems alternative data
| Aug 2023 | 52 |
|---|---|
| Sep 2023 | 52 |
| Oct 2023 | 52 |
| Nov 2023 | 52 |
| Dec 2023 | 52 |
| Jan 2024 | 52 |
| Feb 2024 | 52 |
| Mar 2024 | 52 |
| Apr 2024 | 76 |
| May 2024 | 76 |
| Jun 2024 | 76 |
| Jul 2024 | 76 |
Delcath Systems other data
1.92%
-7.27%
of DCTH is owned by hedge funds
170.52K
-676.60K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 67422 | 0 |
| Aug 2023 | 10550 | 0 |
| Oct 2023 | 14505 | 0 |
| Nov 2023 | 230000 | 0 |
| Dec 2023 | 74000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | AHARON GIL director | Pre-funded Warrants | 603,954 | $0.01 | $6,040 | ||
Option | SALAMON STEVEN A J director | Pre-funded Warrants | 603,954 | $0.01 | $6,040 | ||
Option | ROSALIND ADVISORS, INC. director | Pre-funded Warrants | 603,954 | $0.01 | $6,040 | ||
Option | AHARON GIL director | Tranche B warrants to purchase F-4 Preferred Stock | 500 | $1,000 | $500,000 | ||
Option | SALAMON STEVEN A J director | Tranche B warrants to purchase F-4 Preferred Stock | 500 | $1,000 | $500,000 | ||
Option | ROSALIND ADVISORS, INC. director | Tranche B warrants to purchase F-4 Preferred Stock | 500 | $1,000 | $500,000 | ||
Option | MICHEL GERARD J director, officer.. | Common Stock | 16,666 | $6 | $99,996 | ||
Option | MICHEL GERARD J director, officer.. | Tranche B Warrants to Purchase Common Stock | 16,666 | $6 | $99,996 | ||
Purchase | VUKOVIC VOJO officer: Chief Medical Officer | Common Stock | 40,000 | $3 | $120,000 | ||
Purchase | MICHEL GERARD J director, officer.. | Common Stock | 34,000 | $2.94 | $99,960 |
| Patent |
|---|
Application Filling date: 21 Dec 2021 Issue date: 14 Apr 2022 |
Grant Filling date: 10 Jan 2020 Issue date: 8 Feb 2022 |
Application Filling date: 7 Jul 2021 Issue date: 28 Oct 2021 |
Grant Filling date: 22 Dec 2018 Issue date: 10 Aug 2021 |
Application Filling date: 4 Jun 2020 Issue date: 24 Sep 2020 |
Application Filling date: 10 Jan 2020 Issue date: 14 May 2020 |
Grant Filling date: 12 Jun 2019 Issue date: 25 Feb 2020 |
Application Filling date: 12 Jun 2019 Issue date: 26 Sep 2019 |
Grant Filling date: 10 Sep 2018 Issue date: 6 Aug 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 26 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q1 2023 12 May 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. John Purpura M.S. (1961) Chief Operating Officer | $437,370 |
| Mr. Gerard J. Michel (1963) Chief Executive Officer & Director | $132,000 |
Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
Delcath Systems: Prepare For Substantial Dilution Post-FDA Approval For The Hepzato Kit
Delcath Systems: HEPZATO KIT Should Receive Approval On Aug 14 PDUFA
Rare Buy Picks In June 2023 - From 34 Discerning Analysts
Delcath Systems: Ready To Return To A Previous Winner
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
What's the price of Delcath Systems stock today?
One share of Delcath Systems stock can currently be purchased for approximately $10.55.
-
When is Delcath Systems's next earnings date?
Unfortunately, Delcath Systems's (DCTH) next earnings date is currently unknown.
-
Does Delcath Systems pay dividends?
No, Delcath Systems does not pay dividends.
-
How much money does Delcath Systems make?
Delcath Systems has a market capitalization of 343.71M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 24.05% to 2.07M US dollars.
-
What is Delcath Systems's stock symbol?
Delcath Systems, Inc. is traded on the NASDAQ under the ticker symbol "DCTH".
-
What is Delcath Systems's primary industry?
Company operates in the Healthcare sector and Medical - Specialties industry.
-
How do i buy shares of Delcath Systems?
Shares of Delcath Systems can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Delcath Systems's key executives?
Delcath Systems's management team includes the following people:
- Mr. John Purpura M.S. Chief Operating Officer(age: 64, pay: $437,370)
- Mr. Gerard J. Michel Chief Executive Officer & Director(age: 62, pay: $132,000)
-
How many employees does Delcath Systems have?
As Jul 2024, Delcath Systems employs 76 workers.
-
When Delcath Systems went public?
Delcath Systems, Inc. is publicly traded company for more then 7 years since IPO on 3 May 2018.
-
What is Delcath Systems's official website?
The official website for Delcath Systems is delcath.com.
-
Where are Delcath Systems's headquarters?
Delcath Systems is headquartered at 1633 Broadway, New York, NY.
-
How can i contact Delcath Systems?
Delcath Systems's mailing address is 1633 Broadway, New York, NY and company can be reached via phone at +212 4892100.
Delcath Systems company profile:
Delcath Systems, Inc.
delcath.comExchange:
NASDAQ
Full time employees:
76
Industry:
Medical - Specialties
Sector:
Healthcare
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
1633 Broadway
New York, NY 10019
New York, NY 10019
CIK: 0000872912
ISIN: US24661P8077
CUSIP: 24661P807
